As #Obliteride fundraising season comes to a close, we’re proud of Team Adaptive for showing up and rallying support for lifesaving cancer research at @FredHutch. Thank you to the 82 Adapters who helped raise nearly $60K this year to #CureCancerFaster. #BeAdaptive

The science behind clonoSEQ® continues to build. With more than 300 peer-reviewed publications across ALL, CLL, DLBCL, MCL and multiple myeloma, clonoSEQ is one of the most extensively studied MRD tests in blood cancer.

Adaptive has achieved @My_Green_Lab Certification at the Gold level for our MRD R&D lab. We’re proud of the team who evaluated and updated practices to help reduce waste, conserve water, lower energy use, and implement training to support long-term environmental stewardship.

Attending the AMDM IVD Focus Meeting? Don’t miss Adaptive’s Allison Jacob during her featured presentation on the role of MRD in hematologic malignancies this Thursday, 10/1. amdm.org/2026-focus-meeting.…

A new consensus definition of cure in multiple myeloma marks an important milestone for patients and the myeloma community. Learn more about the new consensus definition and the role of MRD testing: adaptivebio.tech/jfy

Updated NCCN® Guidelines now include a dedicated MRD testing page, identify 10⁻⁶ as the preferred sensitivity and specifically name clonoSEQ® as an FDA-cleared assay for MRD assessment. Read more: adaptivebio.tech/98m

September is #BloodCancerAwarenessMonth. According to @BloodCancerUtd, every 3 minutes someone in the U.S. is diagnosed with leukemia, lymphoma or myeloma. At Adaptive, we’re committed to deeper insight and more informed decisions across the blood cancer journey.

Adaptive has been named a U.S. News & World Report 2026–2027 Best Company to Work For across four categories. We couldn’t be prouder. adaptivebio.tech/sfj #BeAdaptive #BestCompanies

This weekend, Adaptive teammates will come together for Obliteride, each with a personal reason for showing up. Swipe to learn why Chris, Christine and Amanda #Obliteride. #BeAdaptive

clonoSEQ® MRD testing adoption is rooted in strong clinical evidence—but it also needs to work seamlessly in real-world care.